Cancer therapy study pulled before it even started
NCT ID NCT07152236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Started
-
Aug 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The patient fully understands the study procedures and voluntarily signs the informed consent form. 2. Patients diagnosed with tumors that demonstrate positive B7H3 expression in tumor tissues as confirmed by immunohistochemistry (IHC). 3. Presence of at least one extracranial lesion that is measurable according to the RECIST 1.1 criteria; 4. Estimated survival duration of ≥12 weeks; 5. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1 at baseline; 6. Recovery from prior treatment-related toxicities to a level below Grade 2. 7. Adequate hematopoietic and organ function without severe impairment; 8. Availability of suitable venous access for leukapheresis, with no contraindications to the collection of white blood cells. Exclusion Criteria: 1. Patients with a history of or currently diagnosed with other malignant tumors; 2. Presence of brain metastases or clinically significant central nervous system (CNS) disorders; 3. Prior treatment within 14 days or five half-lives (whichever is longer) before blood collection for CAR-T preparation that may interfere with lymphocyte expansion; 4. HIV+,HBV,HCV,EBV,CMV. 5. Positive T-cell interferon-gamma release assay or sputum smear for tuberculosis; 6. Documented history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or significant pulmonary dysfunction; 7. History of severe allergic reactions or known hypersensitivity to any component of the investigational drugs used in the study; 8. Severe cardiovascular disease or uncontrolled refractory hypertension, unless deemed stable and non-interfering with the study by the investigator; 9. Severe hepatic or renal dysfunction, or presence of altered mental status; 10. Active autoimmune or inflammatory neurological disorders; 11. Presence of uncontrolled infections requiring systemic antibiotic, antifungal, or antiviral therapy; 12. Receipt of (attenuated) live vaccines within 4 weeks prior to screening; 13. Individuals with a history of alcohol dependence or substance abuse; 14. Pregnant or lactating women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dongguan Taixin Hospital
Dongguan, Guangdong, 523125, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug that targets two cancer drivers tested in first human study
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Can a Two-Drug combo outsmart advanced cancer?
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- New injectable drug tested for safety in Hard-to-Treat solid tumors
- New antibody drug conjugate tested against advanced cancers